Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany.
ADVITOS GmbH, Munich, Germany.
Artif Organs. 2021 Dec;45(12):1522-1532. doi: 10.1111/aor.14044. Epub 2021 Sep 21.
Disturbed oxygenation is foremost the leading clinical presentation in COVID-19 patients. However, a small proportion also develop carbon dioxide removal problems. The Advanced Organ Support (ADVOS) therapy (ADVITOS GmbH, Munich, Germany) uses a less invasive approach by combining extracorporeal CO -removal and multiple organ support for the liver and the kidneys in a single hemodialysis device. The aim of our study is to evaluate the ADVOS system as treatment option in-COVID-19 patients with multi-organ failure and carbon dioxide removal problems. COVID-19 patients suffering from severe respiratory insufficiency, receiving at least two treatments with the ADVOS multi system (ADVITOS GmbH, Munich, Germany), were eligible for study inclusion. Briefly, these included patients with acute kidney injury (AKI) according to KDIGO guidelines, and moderate or severe ARDS according to the Berlin definition, who were on invasive mechanical ventilation for more than 72 hours. In total, nine COVID-19 patients (137 ADVOS treatment sessions with a median of 10 treatments per patient) with moderate to severe ARDS and carbon dioxide removal problems were analyzed. During the ADVOS treatments, a rapid correction of acid-base balance and a continuous CO removal could be observed. We observed a median continuous CO removal of 49.2 mL/min (IQR: 26.9-72.3 mL/min) with some treatments achieving up to 160 mL/min. The CO removal significantly correlated with blood flow (Pearson 0.421; P < .001), PaCO (0.341, P < .001) and levels (0.568, P < .001) at the start of the treatment. The continuous treatment led to a significant reduction in PaCO from baseline to the last ADVOS treatment. In conclusion, it was feasible to remove CO using the ADVOS system in our cohort of COVID-19 patients with acute respiratory distress syndrome and multiorgan failure. This efficient removal of CO was achieved at blood flows up to 300 mL/min using a conventional hemodialysis catheter and without a membrane lung or a gas phase.
在 COVID-19 患者中,氧合紊乱是主要的临床表现。然而,一小部分患者也会出现二氧化碳清除问题。ADVOS 治疗(ADVITOS GmbH,慕尼黑,德国)采用了一种侵入性较小的方法,即将体外 CO 清除和多器官支持功能结合在单个血液透析设备中,用于肝脏和肾脏。我们的研究目的是评估 ADVOS 系统作为合并多器官衰竭和二氧化碳清除问题的 COVID-19 患者的治疗选择。符合以下条件的 COVID-19 患者有资格入组本研究:严重呼吸功能不全,接受至少两次 ADVOS 多系统(ADVITOS GmbH,慕尼黑,德国)治疗,根据 KDIGO 指南诊断为急性肾损伤(AKI),根据柏林定义诊断为中度或重度急性呼吸窘迫综合征(ARDS),且需要接受机械通气超过 72 小时。共有 9 名 COVID-19 患者(137 次 ADVOS 治疗,中位数为每位患者 10 次治疗)纳入研究,这些患者均存在中重度 ARDS 和二氧化碳清除问题。在 ADVOS 治疗过程中,观察到酸碱平衡迅速得到纠正,并且可以持续清除 CO。我们观察到的中位连续 CO 清除率为 49.2ml/min(IQR:26.9-72.3ml/min),部分治疗达到 160ml/min。CO 清除率与血流量(Pearson 0.421;P<0.001)、PaCO(0.341,P<0.001)和 水平(0.568,P<0.001)呈显著相关。在治疗开始时。连续治疗使 PaCO 从基线显著降低至最后一次 ADVOS 治疗。总之,在我们的 COVID-19 急性呼吸窘迫综合征和多器官衰竭患者队列中,使用 ADVOS 系统去除 CO 是可行的。通过使用常规血液透析导管,在血流量高达 300ml/min 的情况下,无需膜肺或气相,即可实现高效 CO 清除。